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A Becker muscular dystrophy patient was
found to have a single base substitution at
the 5' end of intron 54. This single base
substitution disrupts the invariant GT di-
nucleotide within the 5' donor splice site
and was shown to cause an out of frame
deletion of exon 54 during mRNA pro-
cessing. This is predicted to produce a
truncated dystrophin protein which is
more consistent with a DMD phenotype.
However, small quantities of normal
mRNA are also transcribed and these are
sufficient to produce a reduced amount of
normal molecular weight dystrophin and
give rise to a milderBMD phenotype. This
indicates that a single base substitution at
an invariant dinucleotide of the splice site
consensus sequence may still allow read
through ofthe message and allow the pro-
duction of some normal protein. This
shows that there are a greater number of
possible intronic mutations that can lead
to a mild phenotype and it also underlines
the importance ofperforming cDNA ana-
lysis when screening for small gene al-
terations in the BMD patient population.
(J Med Genet 1996;33:324-327)
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Duchenne muscular dystrophy (DMD) and
Becker muscular dystrophy (BMD) are allelic
X linked neuromuscular disorders char-
acterised by progressive muscle weakness and
severe skeletal muscle degeneration. TheDMD
gene encodes a large 427 kDa cytoskeletal pro-
tein, dystrophin.' The causative mutations in
70% of affected boys are large deletions or
duplications of one or more dystrophin gene
exons,2- while the remaining 30% of affected
subjects presumably have smaller alterations
(nucleotide substitutions, small deletions, or
small insertions) which are more difficult to
detect owing to the very large size of the gene.
The majority of the small mutations identified
in these muscular dystrophy patients have res-
ulted in premature termination ofprotein trans-
lation, giving rise to unstable dystrophins and
the more severe DMD phenotype.6 Un-
fortunately, since these types of mutation do
not produce dystrophin, they provide little or
no information about the structural and func-
tional domains of the protein. On the other
hand, mutations identified in the less severely
affected BMD patients often maintain the
translational reading frame and allow for the
synthesis of a correctly localised dystrophin
protein. For this reason, it becomes important
to identify small gene alterations in BMD
patients. The BMD small mutations provide
insight into the mechanisms involved in gen-
erating the milder phenotype.
Although there have been numerous reports
of DMD point mutations, at present there
are few published BMD point mutations.6
Roberts et al7 reported a G to C transversion
at the 3' end of intron 56 of the dystrophin
gene. This single base substitution caused
partial inactivation of the splice acceptor site
of exon 57, resulting in activation of a cryptic
splice acceptor site located 18 bp downstream
from the normal one, which maintained the
translational reading frame. A similar mutation
that affected normal splicing was reported by
Hagiwara et al.8 This involved a G to T
substitution at position -1 of the 5' splice
site of intron 13 and resulted in the production
of a dystrophin protein with an in frame
deletion of exon 13. Finally, Wilton et al9
described a C to A base change at position
+ 3 of intron 19 which resulted in the deletion
of exon 19 from the dystrophin mRNA. Since
this mutation affected a base in the consensus
sequence that is only 60% conserved,'0 some
normal mRNA was also observed. Thus, the
reported BMD mutations are consistent with
the reading frame rule, which proposes that
deletions or duplications causing BMD allow
for the production of dystrophin because the
translational reading frame is maintained."
We now report a splice site mutation, which
by sequence analysis was predicted to produce
a severely truncated protein and was therefore
more consistent with a DMD mutation. How-
ever, the mutation allowed for the synthesis
of a reduced amount of normal molecular
weight dystrophin and gave rise to a milder
BMD phenotype.
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Figure 1 Western bi
analysis of dystrophit
from normal male mi
samples, the BMD
patient, and a DML
negative control. The
arrow indicates norm
dystrophin at 427 kL
The western blot was




Total RNA was isolated from 30 mg of a muscle
biopsy sample obtained from an unaffected
person and from the affected patient with TRI-
zolTM reagent (BRL). A total of 1 51g of total
RNA was reverse transcribed into cDNA using
0-5 jig4d oligo dT(12 18) (BRL) and 200 U Su-
perscript II reverse transcriptase (BRL) in a
20 VI reaction containing 20 mmol/l Tris-HCl
(pH 8-4), 50 mmol/l KC1, 2.5 mmol/l MgCl2,
0 5 mmol/l dNTPs, and 10 mmol/l DTT. The
lot template and oligo dT primer were initially
n incubated at 70°C for 10 minutes to enhanceuiscle priming and the reverse transcription reaction
was then performed at 42°C for 50 minutes.
tal Seminested PCR was carried out using the
)a. prepared cDNA as template. The first round
reaction was performed in a 100 VI volumebody containing 20 mmol/l Tris-HCl (pH 8 4),
50 mmol/l KCI, 2 mmol/l MgCl2, 10 ng of each
primer (53F: 5'-GAAAGAATTCAGAATCA-
GTGGGATG-3', 59R: 5'-TCGAGGTGAT-
CTTGGAGA-3' and 2-5 U Taq DNA poly-
merase (BRL) for 30 cycles of 94°C for one
minute, 50°C for two minutes, and 72°C for
three minutes with an initial denaturation step
at 94°C for five minutes. An aliquot was re-
moved from the first round PCR product and
used as a template in the second round reaction.
This was carried out as described above except
that 0-2 mmol/I dNTPs and 5 U Taq DNA
polymerase (BRL) were added to the reaction
mix. The nested primer set included the for-
ward primer, 53F, and a reverse primer, 57R
(5'-GTACATCGTTCTGCT-3'). The PCR
products were then separated on a 2-5% agar-
ose gel and visualised with ethidium bromide.
The purified products were sequenced using
the ds DNA Cycle Sequencing System (BRL).
Primers were end labelled with gamma [32p]_
ATP. Product from the sequencing reaction was
analysed using a 5% denaturing polyacrylamide
gel.
ANALYSIS OF GENOMIC DNA
PCR amplification and sequence analysis were
accomplished following the same procedure
as described previously.'2 The oligonucleotide
primers used for PCR amplification and se-
quence analysis were: 54F: 5'-GT-lTGTC-
CTGAAAGGTGGGTTAC-3' and 54R: 5'-
TTATCGTCTTGAACCCTCCCAAG-3'.
PROTEIN ANALYSIS
The immunocytochemical and western blot
procedure for dystrophin were the same as that
described in detail previously.'314
Results and discussion
A muscle biopsy specimen was obtained from
a BMD patient for dystrophin protein analysis.
Western blot analysis using both an N-terminal
antibody and the C-terminal antibody specific
to the last 17 amino acids of the dystrophin C-
terminus (Dys-2, Nova-Castra Labs, New-
castle upon Tyne, UK), indicated the presence
of an apparently normal sized but reduced
dystrophin, approximately 10% of normal (fig
1). Since there was no evidence of a small gene
deletion or duplication, by multiplex PCR and
Southern blotting, we analysed DNA for the
presence of point mutations and cDNA for the
presence of splice type mutations. The DNA
was isolated from the patient's muscle biopsy
and was screened by a heteroduplex analysis
approach,'5 while muscle cDNA was analysed
for splice type mutations as indicated by the
presence of aberrant bands using primer sets
spanning the dystrophin message.
All cDNA PCRs from the patient's muscle
resulted in normal sized products, except for
the product spanning nucleotides 7871-8735
(numbering as in ref 16). The RT-PCR product
from the patient sample yielded two bands: one
band of the expected size (864 bp) but present
at approximately 10% of the normal control,
as well as a more intensely staining product of
reduced size (- 700 bp). The abnormal band
was gel purified and sequenced and was found
to lack nucleotides 8081-8236, which cor-
responds to exon 54 (fig 2). The deletion of
exon 54 results in a translational frameshift
with the new reading frame terminating in exon
55. Therefore, in addition to a stable aberrantly
spliced mRNA that has a frameshifting deletion
of exon 54, the BMD patient transcribes small
quantities of normal mRNA that are sufficient
to produce the approximately 10% levels of
dystrophin observed on the western blot.
Sequence analysis of genomic DNA amp-
lified using primers flanking exon 54 showed a
T to C transition at position + 2 of the 5' splice
site of intron 54. This single base substitution
disrupts the GT dinucleotide within the 5'
donor splice site,'718 causing the deletion of
exon 54 during mRNA processing. For normal
splicing to occur, the splicing system requires
introns to begin with GT and end with AG.
With few exceptions,'9 these dinucleotides are
invariant and required for correct splicing.
Since this was an isolated case of BMD and
given the high frequency ofgermline mosaicism
in Duchenne muscular dystrophy, the pos-
sibility of somatic mosaicism for the point
mutation exists. However, sequence analysis
from the muscle biopsy showed only the ab-
normal sequence. It is therefore unclear how
the splicing apparatus was able to recognise
the mutant splice donor site and still produce
some normal message. In comparison, the
BMD mutation described by Wilton et al9 in-
volved a base outside the highly conserved GT
dinucleotide and therefore resulted in some
normal transcript.
A scoring system was devised by Shapiro and
Senapathy20 to determine optimal splice site
sequences based on the frequency of each nuc-
leotide in normal splice sequences. The wild
type sequence at the 5' donor site of intron 54
(AG:GTATGA) scores 81% using this method,
indicating a high degree of similarity to the
actual consensus sequence (AG:GTA/CAGT)
established by Mount.'8 The mutated sequence
at this site (AG:GCATGA) scores -64% and
since normally used splice site sequences have
a score > 70, the point mutation at the invariant
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Figure 2 Dystrophin cDNA sequence analysis. (A) Portions of the sequencing gel with a normal control on the left and
the BMD patient on the right are shown. A comparison of the nucleotide sequences of the two PCR products showed that
the patient sample is deleted for exon 54, and that exon 53 is precisely joined to exon 55. (B) The two PCR products
represent normally spliced (above) and misspliced (below) dystrophin mRNA. Exon 54 has been skipped owing to the T
to C transition at the donor splice site of intron 54. Exons are represented by open boxes while solid lines represent introns.
GT dinucleotide is predicted to prevent normal
mRNA splicing.
This patient had a mild phenotype and was
shown to produce a low level of dystrophin.
The patient is at present 9 years old and can
walk well on both his heels and toes. There is
only mild slowing when he runs and he can
rise from a squat position with only minimal
hand support on his knee. Thus, the low abund-
ance of normal transcript was sufficient to syn-
thesise enough dystrophin to give rise to the
milder phenotype. It has been observed in other
genetic diseases that variations outside the
highly conserved 5' GT or 3' AG dinucleotides
often result in the production ofboth abnormal
and normal spliced mRNA transcripts. We have
shown that a point mutation at the invariant
dinucleotide of the consensus sequence may
still allow read through of the mutation and
production of some normal transcript. This
increases the number of possible intronic mut-
ations that can occur in the dystrophin gene,
which allow for the synthesis of sufficient levels
of dystrophin to produce the milder phenotype.
This may also account for the fact that very
few BMD mutations have been identified using
genomic DNA analysis. Intron mutations that
affect splice sites, branch sites, or create cryptic
splice sites may be responsible for producing
the reduced amount of dystrophin and the
milder phenotype in many of the BMD
patients. Strategies based on cDNA analysis
will therefore be most successful in finding
more BMD small mutations.
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